Focus on FAPI Newsletter – Q4 2025

Dear FAPI Community,

This newsletter gives me the opportunity to pause and reflect both on recent accomplishments and what lies ahead. The last year has been pivotal for the FAPI program.  We’ve grown our community dynamically, through new collaborations in our Global Outreach Program, through expansion of [¹⁸F]FAPI-74 production now to SEVEN SOFIE radiopharmacies across the country (with more to come), and through the investigators, clinical staff, and, of course, patients that were critical to the completion of our Phase 2 [¹⁸F]FAPI-74 trials.

I am absolutely thrilled to share that on November 14, SOFIE launched FAPI-GO, our [¹⁸F]FAPI-74 study on gastroesophageal cancers.  We are in the process of activating 18 total sites across the US over the next seven months. Further, FAPI-PRO, our [¹⁸F]FAPI-74 study on pancreatic cancer, is scheduled to launch the end of December.  This would not be possible without the collective and diligent efforts of many team members and partners, for which we are so grateful.

As you may have noticed, our beloved SOFIE logo turned purple in November to recognize Pancreatic Awareness Month. Pancreatic cancer is the third leading cause of cancer-related deaths in the US (following lung and colorectal). We are proud to support the efforts of organizations such as the Pancreatic Cancer Action Network to bring awareness and resources to patients and their loved ones.

We have also revamped our educational resources on the SOFIE website to enable easier searches of curated FAPI content.

As SOFIE continues our clinical development efforts in 2026, we look forward to broadening and deepening our community, with the shared goal of improving patient lives.

Have a peaceful holiday season and, as always, we invite you to provide feedback.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

Sherly Mosessian, Ph.D.